



THERAPEUTIC PIPELINE

monash.edu/industry/license-technologies

| Application | Target – ID | Target – Hit | Lead Series | Lead Optimisation | PreClinical | Clinical |
|-------------------------------|---|--------------|---|---|-------------|-----------------------------|
| Inflammation & immunity | Medicinal supplement | | | | | AI diseases/Type I diabetes |
| | Anti-inflammatory (biologic) | | | Inflammatory diseases | | |
| | Anti-CCR6 (mAb) | | | AI diseases | | |
| | Antigen-specific Tregs | | | Lupus | | |
| | S1P receptor modulators (small molecule) | | | IBD | | |
| | Undisclosed target (small molecule) | | | Pulmonary hypertension | | |
| | Novel pathway (small molecule) | | | Asthma | | |
| Oncology | CLEC9A mAb vaccine delivery platform | | | Cancer and infectious diseases | | |
| | Dual-targeted BET/PI3K inhibitors (small molecule) | | | Haematological and other cancers | | |
| | Two immune checkpoints for T cell therapy | | Solid tumour and haematological cancers | | | |
| Infectious Diseases | Ivermectin - repurposing | | | | | Coronavirus |
| | Chemotactic antibiotic (peptide) | | | Bacterial infections | | |
| | Anti-microbial INOS-SPSB inhibitors (peptide) | | | Protozoal and bacterial infections | | |
| | Anti-α-Plasminogen (mAb) | | | C. difficile (and others) | | |
| | Bedaquiline derivatives (small molecule) | | | Tuberculosis | | |
| | Splice switch (oligonucleotide) | | | Coronavirus | | |
| Fibrosis / Metabolic Diseases | Exosomes from amniotic epithelial stem cells (biologic) | | | Lung, liver and kidney fibrosis | | |
| | Selective AT2 receptor agonists (peptide) | | | Renal, liver, kidney, lung and cardiac fibrosis | | |
| | GC Rx inhibitors (small molecule and combination) | | Obesity | | | |
| CNS | Inhibitors of undisclosed target (miRNA) | | | Huntington's, Alzheimer's and Parkinson's Diseases | | |
| | Reduction of beta-amyloid (peptide) | | | Alzheimer's Disease | | |
| | Anti-vWF (mAb) | | | Thrombosis | | |
| Women's Health | MTX + gefitinib (small molecule drug combination) | | | | | Ectopic pregnancy |
| | Super-GDF9 (biologic) | | | Female infertility (IVM) | | |
| | Inhibin analogues (biologic) | | | Post-menopausal complications | | |
| | AMH analogues (biologic) | | | Oncofertility | | |
| Other | Induced Trophoblast Stem Cells (iTSC) | | | Regenerative medicine | | |
| | Novel target (small molecule) | | | Polycystic Kidney Disease (orphan disease indication) | | |
| | Engineered growth factors (biologic) | | | Treatment of wounds; bone regeneration | | |
| | Engineered anti-inflammatory and growth factor (biologic) | | | Treatment of wounds; bone regeneration; inflammatory diseases | | |
| | Skeletal muscle regeneration (biologic) | | | Musculoskeletal diseases | | |
| | Gene therapy | | Musculoskeletal diseases | | | |

CONTACT US

Monash Enterprise
 T: +61 3 9905 9910
 E: innovation@monash.edu
 W: monash.edu/industry





BIOMEDICAL OPPORTUNITIES

monash.edu/industry/license-technologies



NEXT GENERATION TECHNOLOGIES

- Neo-epitope detection and validation



CELL THERAPY / REGENERATIVE MEDICINE

- Engineering TCR with enhanced affinity
- Induced Trophoblast Stem Cells (iTSC)
- Functionally tuneable peptide hydrogels (CVD/CNS)
- Exosomes from amniotic stem cells (fibrosis and neurodegenerative diseases)



VACCINES

- MicroCube vaccine platform - bioengineered protein crystals to present a range of antigens (oncology and infectious diseases)



DRUG DELIVERY

- Anti-abuse drug formulation
- Functionally tuneable peptide hydrogels for sustained delivery (small molecule, cell therapy, nucleic acids)
- Lipopeptide-based nanoparticle gene delivery system (oncology and infectious diseases)
- Sustained-release implant



DIAGNOSTICS

- Biomarker and biomarker detection kit for breast cancer
- Biomarker for breast cancer/PET ligand for oncology
- Diagnostic for personalised treatment of CF
- Multiplexed platform for immune response monitoring (allergy and infectious diseases)
- PET ligand for MS treatment



SCREENING TECHNOLOGY / OTHER

- Microfluidic device for BBB detection (detection of toxins etc.)
- rPlasminogen manufacture

MONASH TECHNOLOGY RESEARCH PLATFORMS

- Imaging technologies including Cryo EM, X-ray
- Fragment screening
- Monash Animal Research Platform (CRISPR)
- Monash Antibody Technologies Facility
- Centre for Drug Candidate Optimisation

All platforms ISO-accredited: monash.edu/research/infrastructure



CONTACT US

Monash Enterprise
 T: +61 3 9905 9910
 E: innovation@monash.edu
 W: monash.edu/industry